zjkc rTMS & Phototherapy: New Hope for Dementia Patients

WUHAN, China - Aug. 26, 2025 - PRLog -- With global aging, Alzheimer's (AD) and Parkinson's (PD) pose major health risks—over 55 million live with dementia (60-70% AD, WHO 2023), and PD affects 10 million (to double by 2040, Dorsey et al. 2018). Traditional treatments have limits, but repetitive transcranial magnetic stimulation (rTMS) + phototherapy is promising.

AD involves beta-amyloid plaques/tau tangles (damaging neurons) and low acetylcholine; PD causes dopamine neuron loss (motor issues) and alpha-synuclein clumps.

rTMS uses magnetic fields to adjust neuron activity, boosting neuroplasticity. Phototherapy (near-infrared) fuels mitochondria (raises ATP), reduces inflammation, and regulates neurotransmitters (Hamblin 2017).

Studies show efficacy: A JAMA Neurology meta-analysis (Brunoni et al. 2014) found it improves AD patients' cognition/daily skills; Movement Disorders research (Zanjani 2015) eases PD's motor/non-motor symptoms, synergizing with meds.

It's non-invasive, low-side-effect, and personalized. For reliable tools, zjkc's Transcranial Magnetic Stimulation Device (https://zjkcshop.com/products/transcranial-magnetic-stimulation-tms-therapy-for-depression-parkinsons-alzheimers) fits—precision-engineered for AD/PD personalized care.

Challenges include unclear efficacy duration and lacking guidelines, but future tech and multi-therapy combinations hold promise.

#rTMSPhototherapyForDementia #zjkcTMSTherapy #AlzheimersTreatment #ParkinsonsCare #zjkcBrainHealth